---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-044805"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:18:21.386984+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allurion Q4 revenue $5.6M, down 32% YoY; guides 2025 rev ~$30M, 50% opex cut

## Summary
- Q4 revenue $5.6M (down 32% YoY); full-year $32.1M; 2025 guidance ~$30M.
- Q4 operating loss $17.1M vs $25.7M YoY, includes $4.6M restructuring and financing costs.
- Q4 gross margin 45% vs 78% YoY; full-year 67%; expects margin expansion in 2025.
- Sales resumed in France Feb 12, 2025; positive AUDACITY FDA trial readout; next-gen balloon launched.
- Cash $15.4M at Dec 31, 2024; recent financings expected to fund through potential FDA approval in 2026.

## SEC filing metadata
- accession: 0000950170-25-044805
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000095017025044805/0000950170-25-044805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000095017025044805/alur-20250326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-044805
- JSON: https://secwatch.observer/filing/0000950170-25-044805.json
- Plain text: https://secwatch.observer/filing/0000950170-25-044805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.